1Stroke Risk by CHA₂DS₂-VASc Score
| Score | Annual Stroke Risk | Anticoagulation (ESC 2020) |
|---|---|---|
| 0 (M) / 1 (F) | 0% | None |
| 1 (M) / 2 (F) | 1.3% | Consider OAC |
| 2 | 2.2% | OAC Recommended |
| 3 | 3.2% | OAC Recommended |
| 4 | 4.0% | OAC Strongly |
| 5 | 6.7% | OAC Strongly |
| 6 | 9.8% | OAC Strongly |
| 7 | 9.6% | OAC Strongly |
| 8 | 6.7% | OAC Strongly |
| 9 | 15.2% | OAC Mandatory |
ESC 2020 Anticoagulation Decision
The 2020 ESC AF guidelines provide clear, sex-specific anticoagulation thresholds:
- Men with score ≥2 / Women with score ≥3: Oral anticoagulation recommended (Class I, Level A)
- Men with score 1 / Women with score 2: Oral anticoagulation should be considered (Class IIa, Level B)
- Men with score 0 / Women with score 1: Anticoagulation not recommended
- Female sex alone (score 1 in a woman with no other factors): Does NOT warrant anticoagulation
DOACs vs Warfarin in AF
For non-valvular AF, DOACs (direct oral anticoagulants) are preferred over warfarin per ESC 2020, AHA/ACC 2023, and NICE guidelines:
- Apixaban (Eliquis): 5 mg BD — lowest bleeding risk, preferred in elderly and CrCl 25–50 mL/min. Reduce to 2.5 mg BD if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥133 µmol/L
- Rivaroxaban (Xarelto): 20 mg OD with evening meal — once daily improves adherence. Reduce to 15 mg OD if CrCl 15–50 mL/min
- Dabigatran (Pradaxa): 150 mg BD or 110 mg BD if age ≥80 or on verapamil. Avoid if CrCl <30 mL/min — 80% renal clearance
- Warfarin: Reserved for valvular AF (especially mitral stenosis or mechanical valves), severe renal failure (CrCl <15), or when DOACs unavailable. Target INR 2–3
What CHA₂DS₂-VASc Stands For
- Congestive Heart Failure (1 point)
- Hypertension (1 point)
- A₂ge ≥75 years (2 points)
- Diabetes Mellitus (1 point)
- S₂troke / TIA / Thromboembolism history (2 points)
- Vascular Disease — prior MI, peripheral arterial disease, aortic plaque (1 point)
- Age 65–74 years (1 point)
- Scategory — Female Sex (1 point, sex modifier not independent risk factor)
Limitations and Important Notes
CHA₂DS₂-VASc identifies who needs anticoagulation but not who to withhold it from. Bleeding risk should be assessed simultaneously using HAS-BLED score. A high HAS-BLED score is not a reason to withhold anticoagulation — it identifies modifiable bleeding risk factors to address. Anticoagulation decisions must account for patient preferences, comorbidities, renal and hepatic function, and medication interactions.
2Frequently Asked Questions
3About the CHA2DS2-VASc Score
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and the leading cause of cardioembolic stroke worldwide. In India, AF prevalence is approximately 0.5-1% of the adult population and is rising with the ageing demographic. The CHA2DS2-VASc score, developed by Lip et al. in 2010, provides a simple framework for estimating annual stroke risk and guiding anticoagulation decisions in non-valvular AF.
The score refined the earlier CHADS2 system by adding vascular disease, age 65-74, and female sex as additional risk modifiers, improving identification of truly low-risk patients who can safely avoid anticoagulation. A CHA2DS2-VASc score of 0 in men (1 in women) identifies a very low-risk group (~0.5% annual stroke risk) for whom the bleeding risk of anticoagulation likely outweighs benefit.
In Indian practice, anticoagulant choice is influenced by cost and access. DOACs (direct oral anticoagulants) — apixaban, rivaroxaban, dabigatran — are now the preferred agents over warfarin per ESC, AHA, and Cardiological Society of India guidelines. However, cost remains a barrier and warfarin remains widely used. For patients on warfarin, achieving a time in therapeutic range (TTR) >70% is essential — if TTR cannot be maintained, switch to a DOAC if feasible.